- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03297008
Biomarkers in Saliva and Stool
Understanding Innate and Adaptive Immunological Response in Stool and Saliva Samples in Healthy Donors
Study Overview
Detailed Description
Many soluble factors found in blood can be detected in saliva and stool. Often levels of these factors are found to correlate between body fluids, though the exact relationship between systemic (blood) and local (saliva and stool) immunity is not well established yet. Saliva- and stool-associated factors are produced in the oral cavity and in the gut, which represent mucosal sites that potentially come in direct contact with pathogens. Thus, the levels of mucosal-associated soluble factors can better represent the local immune response at these sites.
It is becoming clear now that saliva and stool can be used to analyze inflammatory responses as well. In a recent study, 20 possible salivary biomarkers related to obesity were surveyed and the authors found four biomarkers that exhibit significant change with increasing body weight in a pediatric population. Salivary C-reactive protein (CRP), salivary insulin, leptin and adiponectin were found to be different in obese children compared to healthy normal weight children. This data suggests that saliva could be a useful blood surrogate for the study of metabolic complications of obesity in children, where repeated blood sampling can be both traumatic and difficult. The results of this study also provide insight into the early development of metabolic disease in children. (Goodson, Kantarci et al. 2014). In another study, cytokines-chemokines-growth factors (CCGFs) were measured using multiplex bead assays and compared between plasma, saliva and urine collected from 20 male and female healthy volunteers. By analyzing more than one sample types from the same subject would increase the possibility of identifying biomarker(s) for any inflammatory disease. In this study, gender-specific CCGFs were also observed and concentrations of some CCGFs varied between genders. This information is also valuable for biomarker discovery that by combining male and female subjects in a clinical trial would eliminate false discovery of biomarkers (Khan 2012).
The mucosal immune system can be also understood by analyzing stool samples. In a recent study, it is shown that a particular bacterial predominance, such as Bifidobacterium sp., may enhance thymic development and immune responses to both oral and parenteral vaccines early in infancy, whereas a deviation from this pattern, resulting in greater bacterial diversity, may cause systemic inflammation (neutrophilia) and lower vaccine responses. Thus, vaccine responsiveness may be improved by promoting intestinal Bifidobacteria sp. and minimizing dysbiosis early in infancy (Huda, Lewis et al. 2014). Of note, the hallmark of adequate mucosal immune responses is the production of secretory immunoglobulin A (SIgA), which can prevent infection and remove antigen crossing the mucosal barrier.SIgAis also imperative to establish mutualism between host and the intestinal microbiota (Maynard, Elson et al. 2012). Hence measurement of SIgA can help to assess the mucosal immunity.
Despite saliva and stool samples are increasingly studied in order to assess mucosal immune response and/or clinical outcomes, there is still a lack of established methodology to be routinely used in diagnostic laboratories and clinical trials. Therefore our aim is to collect saliva and stool samples using the salimetrics swab and self-stool collection kit from a cohort of 60 volunteers, process and store samples in a standardized manner. Following this, we intend to perform immunological assays such as enzyme-linked immunosorbent assay, multiplex bead assay and Immunocap to correlate the salivary and fecal levels of biomarkers in healthy donors. As this method is non-invasive, we believe that more people will be willing to donate samples. It is also easy to self-collect and it is cost efficient.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 138671
- Danone Nutricia Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
• Healthy volunteers of age 0-60 years old
Exclusion Criteria:
- Volunteers with any known infectious diseases, such as HIV and Hepatitis B
- Volunteers with any acute or chronic illness, such as chronic inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis)
- Volunteers with oral diseases/ulcers
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Establish methods to detect immune markers in non-invasive samples: Saliva and stool in healthy volunteers
Time Frame: 1 year after completion of recruitment
|
ELISA RSV specific Immunoglobulin in saliva
|
1 year after completion of recruitment
|
Establish methods to detect immune markers in non-invasive samples: Saliva and stool in healthy volunteers
Time Frame: 1 year after completion of recruitment
|
ELISA Rotavirus specific Immunoglobulin in stool
|
1 year after completion of recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in RSV-specific Immunoglobulins between age groups.
Time Frame: 1 year after completion of primary outcome
|
Correlation between age and RSV-specific Immunoglobulins in saliva
|
1 year after completion of primary outcome
|
Difference in RSV-specific Immunoglobulins between age groups.
Time Frame: 1 year after completion of primary outcome
|
Correlation between age and rotavirus-specific Immunoglobulins in stool
|
1 year after completion of primary outcome
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Establish methods to detect immune markers in non-invasive samples: Saliva and stool in healthy volunteers
Time Frame: 1 year after completion of primary outcome
|
ELISA RSV specific Immunoglobulin in stool
|
1 year after completion of primary outcome
|
Establish methods to detect immune markers in non-invasive samples: Saliva and stool in healthy volunteers
Time Frame: 1 year after completion of primary outcome
|
ELISA Rotavirus specific Immunoglobulin in saliva
|
1 year after completion of primary outcome
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elena Sandalova, PhD, Nutricia Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BIO-MK-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on No internvetion
-
University of California, San FranciscoNational Cancer Institute (NCI); National Institutes of Health (NIH)Not yet recruitingColorectal Cancer | Colon Cancer | Cancer ColorectalUnited States
-
RadiancyCompletedMild to Moderate Chronic Low Back PainIsrael
-
The Hong Kong Polytechnic UniversityRecruitingChronic Low Back PainHong Kong
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
RTI InternationalNo Means No WorldwideCompleted
-
University of California, Santa BarbaraCompleted
-
HealthpointCompletedVenous Leg Ulcer (VLU)Germany, Poland, Belgium, Hungary, Czechia
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Fraunhofer-Institute of Toxicology and Experimental...UCB PharmaCompleted